share_log

复星医药(600196.SH):许可产品获药品注册批准

fosun pharma (600196.SH): Licensed products obtain pharmaceutical registration approval.

Gelonghui Finance ·  Nov 27 02:26

Gelonghui, November 27丨Fosun Pharmaceutical (600196.SH) announced that its holding subsidiary Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. has recently been approved by the State Drug Administration for marketing license for injectable botulinum toxin (1 trademark in China: Daxfield, project code: RT002) to treat neck dystonia in adults.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment